logo-loader
AIM ImmunoTech Inc.

Hemispherx Biopharma promotes Ellen Lintal to chief accountant post

Lintal joined the Florida biopharmaceutical group in 2018 as a vice-president of finance & control

cancerous cells
Hemispherx is focusing its research and development efforts on advancing its flagship cancer drug Ampliglen as an immuno-therapy

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) has tapped Ellen Lintal as its new chief accounting officer.

Lintal joined the Florida biopharmaceutical group in 2018 as a vice-president of finance and control.

READ: Hemispherx Biopharma kicks off Phase 1 trial to treat advanced breast cancer with key drug Ampligen

Prior to coming on board at Hemispherx, Lintal spent a decade at an undisclosed international non-profit organization, where she served as a chief financial officer and a senior vice-president of finance and control. Her career also includes accounting experience while working for Corning, the Carlisle Companies and AGY.

“Ms. Lintal has done a superb job since arriving at Hemispherx and will make an excellent chief accounting officer,” said CEO Thomas Equels in a statement.

Hemispherx is focusing its research and development efforts on advancing its flagship cancer drug Ampliglen as an immuno-therapy. The drug is currently being evaluated to treat nine different types of tumors.

Contact Ellen Kelleher at [email protected]

 

Quick facts: AIM ImmunoTech Inc.

Price: $2.10

Market: NYSE
Market Cap: $5.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

2 min read